Innovative therapies for disorders of the central nervous system. Lead program is an SSIA targeting 5-HT2A receptors for psychosis. Clinical stage.
San Diego, CA
NASDAQ: ACAD
Innovative therapies for disorders of the central nervous system. Lead program is an SSIA targeting 5-HT2A receptors for psychosis. Clinical stage.
San Diego, CA
NASDAQ: ACAD
Recent Comments